ULTRAsensitive PLAsmonic devices for early CAncer Diagnosis
ULTRAPLACAD is a project funded by the European Union’s Horizon 2020 research and innovation programme, dealing with the development of a compact plasmonic-based device with an integrated microfluidic circuit and functionalized nanostructures for the detection of DNA, microRNA and tumor autoantibodies.
ULTRAPLACAD aims at the development of a novel robust in vitro diagnostic system for early cancer diagnosis, prognosis, patient follow-up and therapy efficacy assessment based on molecular analysis of peripheral blood (liquid biopsy).
Concept pictures of ULTRAPLACAD disposable plasmonic chip (left) and compact reader (right). – © ULTRAPLACAD
The use of innovative optical analytical techniques that take advantage of plasmonic metallic nanostructures will advance the state-of-art of colorectal cancer biomarker detection. The aim is to detect these cancer biomarkers circulating in blood with improvement in sensitivity, reduction in cost of platform compared to today’s available techniques and analysis time less than 1h.